Welcome to our dedicated page for SHP news (Ticker: SHP), a resource for investors and traders seeking the latest updates and insights on SHP stock.
This page aggregates news content where the symbol SHP appears in connection with ShangPharma (NYSE: SHP), as cited in Business Wire releases about investor and executive William Dai. In these articles, ShangPharma is mentioned as one of the companies where he previously served as Chief Financial Officer.
The news items themselves focus on ShangBay Capital, a venture capital firm specializing in healthcare investments and medtech ventures, and on William Dai’s recognition in GrowthCap’s Top 25 Healthcare Investors lists. Within that context, ShangPharma (NYSE: SHP) is referenced as part of his prior corporate finance and capital markets experience.
Readers using this page can review how SHP is cited historically in relation to ShangPharma and to William Dai’s executive background. The coverage includes information about his investment track record, the number of portfolio companies and exits at ShangBay Capital, and his board roles at various healthcare and medtech companies, as described in the Business Wire releases.
Because the available articles do not provide detailed operational or strategic information about ShangPharma itself, this news feed should be viewed as a contextual archive showing how the SHP ticker is referenced in relation to ShangPharma and to William Dai’s career history.
William Dai, Founding Managing Partner at ShangBay Capital, has been named among GrowthCap's Top 25 Healthcare Investors for 2025, marking his third recognition on this prestigious list. Since founding ShangBay Capital in 2015, Dai has led the firm to invest in 72 portfolio companies with multiple successful exits, including Ceribell, one of the best recent Medtech IPOs. The firm has syndicated 26 portfolio companies with major strategics.
Dai currently serves on the boards of Luminopia, Aqua Medical, Meditrina, FemDx, and YorLabs. With over 20 years of experience in corporate finance, M&A, and capital markets, he previously held CFO positions at ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE: NPD), Microport Scientific Corporation, and Boston Scientific China.
ShangBay Capital's William Dai has been recognized among the top 25 healthcare investors for 2024 by GrowthCap. William Dai, the Founding Managing Partner at ShangBay Capital, has made significant contributions to the healthcare sector with a focus on medtech ventures. His expertise in corporate finance and mergers and acquisitions has led to the success of ShangBay Capital, nurturing 67 portfolio companies and achieving successful exits.
ShangBay Capital, a healthcare-focused venture capital firm, announces that William Dai has been recognized by GrowthCap as one of the top healthcare investors. This recognition highlights his significant contributions to advancing medical technologies. Since founding ShangBay in 2015, Dai has led investments in 55 portfolio companies, achieving multiple successful exits. His previous experience includes serving as CFO for several companies, including ShangPharma (NYSE: SHP) and Nepstar Corporation (NYSE: NPD). Dai emphasizes ShangBay's commitment to supporting entrepreneurs addressing unmet clinical needs.
